Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Glycomimetics Inc
(NQ:
GLYC
)
0.1584
-0.0001 (-0.06%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Glycomimetics Inc
< Previous
1
2
3
4
5
6
Next >
GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan
July 25, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
7 Sorry Biotech Stocks Set to Make Investors Sad
July 22, 2024
Biotech stocks can be extremely challenging because it takes a long time to bring a therapy to market. Here are some biotech stocks to sell.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
June 26, 2024
It's time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning!
Via
InvestorPlace
Why GlycoMimetics Stock is Trading Higher Monday
June 25, 2024
On Tuesday, the chief medical officer Edwin Rock disclosed in a Form4 that he bought 305 thousand shares in the company.
Via
Benzinga
Earnings Outlook For GlycoMimetics
March 26, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
June 25, 2024
Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning!
Via
InvestorPlace
$1M Bet On This Penny Stock? Check Out These 4 Stocks Under $2 Insiders Are Aggressively Buying
June 21, 2024
Via
Benzinga
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
June 04, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
May 29, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
GLYC Stock Earnings: GlycoMimetics Misses EPS for Q1 2024
May 09, 2024
GLYC stock results show that GlycoMimetics missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Dow Surges Over 100 Points; EyePoint Pharmaceuticals Shares Plunge
May 06, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Crude Oil Gains 1%; TreeHouse Foods Shares Fall After Q1 Results
May 06, 2024
Via
Benzinga
Exposures
Fossil Fuels
12 Health Care Stocks Moving In Monday's Intraday Session
May 06, 2024
Via
Benzinga
Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views
May 06, 2024
Via
Benzinga
Topics
Earnings
Exposures
Financial
GlycoMimetics' Uproleselan Flunks In Late Stage Leukemia Study, Shares Sink
May 06, 2024
Get insights on GlycoMimetics Inc's Phase 3 study results for uproleselan in R/R AML patients. Explore survival rates, adverse events, and future analyses.
Via
Benzinga
Why Is Acutus Medical (AFIB) Stock Down 41% Today?
May 06, 2024
Acutus Medical stock is down on Monday after the company reported a delisting notice that will hit AFIB shares later this week.
Via
InvestorPlace
Why Is GlycoMimetics (GLYC) Stock Down 77% Today?
May 06, 2024
GlycoMimetics stock is falling on Monday with heavy trading of GLYC after posting lackluster results from a Phase 3 trial of uproleselan.
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 06, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
May 06, 2024
It's time to dive into the biggest pre-market stock movers with all of the hottest news worth reading about on Monday morning!
Via
InvestorPlace
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
May 06, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
April 25, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
April 02, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
March 27, 2024
Via
Benzinga
GLYC Stock Earnings: GlycoMimetics Beats EPS for Q4 2023
March 27, 2024
GLYC stock results show that GlycoMimetics beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
March 27, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Earnings Scheduled For March 27, 2024
March 27, 2024
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million.
Via
Benzinga
GlycoMimetics: A Potential Game Changer In Blood Cancers With Near-Term Catalysts
March 21, 2024
Glycomimetics' Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute Myeloid Leukemia (AML) after 6 years in pivotal studies.
Via
Talk Markets
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
March 13, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
February 26, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
February 12, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.